SCHEMBL27211484

SCHEMBL27211484

CCOc1cc(C=CC(=O)CC)ccc1O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 3/20 0.86
IAPP P10997 1/20 0.68
ALDH1A1 P00352 2/20 0.63
APP P05067 4/20 0.62
ABCB1 P08183 3/20 0.62
MAOB P27338 3/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
MAPT P10636 3/20 0.62
BACE1 P56817 3/20 0.62
CYP2D6 P10635 2/20 0.62
CYP2C9 P11712 2/20 0.62
TSHR P16473 2/20 0.62
HSD17B10 Q99714 2/20 0.62
AKR1B1 P15121 2/20 0.62
MAOA P21397 2/20 0.62
ALPI P09923 2/20 0.62
ALPG P10696 2/20 0.62
HDAC3 O15379 2/20 0.62
HDAC1 Q13547 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Curcumin SCHEMBL8965258 0.93 TOP2A (1.00) TOP2AALDH1A1APPABCB1MAOB
Ethyl Curcumin SCHEMBL8965263 0.93 TOP2A (1.00) TOP2AALDH1A1APPABCB1MAOB
SCHEMBL14157952 0.89 TOP2A (0.68) TOP2AIAPPALDH1A1APPABCB1
SCHEMBL1374497 0.87 TOP2A (0.89) TOP2AALDH1A1APPABCB1MAOB
SCHEMBL27686673 0.87 TOP2A (0.89) TOP2AALDH1A1APPABCB1MAOB
SCHEMBL29929626 0.87 TOP2A (0.89) TOP2AALDH1A1APPABCB1MAOB
SCHEMBL3859807 0.87 APP (0.83) TOP2AIAPPALDH1A1APPABCB1
SCHEMBL3859809 0.87 APP (0.83) TOP2AIAPPALDH1A1APPABCB1
SCHEMBL4621488 0.87 TOP2A (0.78) TOP2AALDH1A1APPABCB1MAOB
SCHEMBL31380860 0.87 TOP2A (0.78) TOP2AALDH1A1APPABCB1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011293-A1 LEUKOTRIENE SYNTHESIS INHIBITORS NAEGIS PHARMACEUTICALS INC. (CA) 2025-01-09 US disclosed
US-11976052-B2 Leukotriene synthesis inhibitors NAEGIS PHARMACEUTICALS INC. (CA) 2024-05-07 US disclosed
US-20220064132-A1 LEUKOTRIENE SYNTHESIS INHIBITORS NAEGIS PHARMACEUTICALS INC. (CA) 2022-03-03 US disclosed
CN-113784713-A Leukotriene synthesis inhibitors 纳吉斯制药股份有限公司 2021-12-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064132-A1 LEUKOTRIENE SYNTHESIS INHIBITORS LTC4S, LTB4R2, LTA4H TOP2A 4511/4885IAPP 2392/4885ALDH1A1 2274/4885
US-11976052-B2 Leukotriene synthesis inhibitors LTC4S, LTB4R2, LTA4H TOP2A 4511/4885IAPP 2392/4885ALDH1A1 2274/4885
US-20250011293-A1 LEUKOTRIENE SYNTHESIS INHIBITORS LTC4S, LTB4R2, LTA4H TOP2A 4511/4885IAPP 2392/4885ALDH1A1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.